{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:58:58Z","timestamp":1793210338869,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-09653-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:46:22Z","timestamp":1770846382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Agent-based modeling of cellular dynamics in adoptive cell therapy"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-521X","authenticated-orcid":false,"given":"Yujia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Casarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-8397","authenticated-orcid":false,"given":"May","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-6750","authenticated-orcid":false,"given":"Vakul","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-5863","authenticated-orcid":false,"given":"Merve","family":"Dede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0287","authenticated-orcid":false,"given":"Mayra","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Dondossola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7850-4925","authenticated-orcid":false,"given":"Ludovica","family":"La Posta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-0454","authenticated-orcid":false,"given":"Rafet","family":"Ba\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9599-2246","authenticated-orcid":false,"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5279","authenticated-orcid":false,"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"9653_CR1","doi-asserted-by":"crossref","unstructured":"Li, H., Song, W., Li, Z. & Zhang, M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front. Immunol. 13, 992232, (2022).","DOI":"10.3389\/fimmu.2022.992232"},{"key":"9653_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederst\u00e4dt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557\u2013575 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"9653_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","volume":"19","author":"M Boyiadzis","year":"2017","unstructured":"Boyiadzis, M. et al. Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 19, 1225\u20131232 (2017).","journal-title":"Cytotherapy"},{"key":"9653_CR4","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","volume":"8","author":"BA Williams","year":"2017","unstructured":"Williams, B. A. et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget 8, 89256\u201389268 (2017).","journal-title":"Oncotarget"},{"key":"9653_CR5","doi-asserted-by":"crossref","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: A phase 1\/2 trial. Nat. Med. 2024 30:3 30, 772\u2013784 (2024).","DOI":"10.1038\/s41591-023-02785-8"},{"key":"9653_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial.  Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"9653_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","volume":"10","author":"S Arai","year":"2008","unstructured":"Arai, S. et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 10, 625\u2013632 (2008).","journal-title":"Cytotherapy"},{"key":"9653_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14653249.2010.515582","volume":"13","author":"MA Geller","year":"2011","unstructured":"Geller, M. A. et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13, 98\u2013107 (2011).","journal-title":"Cytotherapy"},{"key":"9653_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299\u2013308 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"9653_CR10","doi-asserted-by":"crossref","unstructured":"Marofi, F. et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res. Ther. 12, 374 (2021).","DOI":"10.1186\/s13287-021-02462-y"},{"key":"9653_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei, H., Daher, M. & Rezvani, K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br. J. Haematol. 193, 216\u2013230 (2021).","journal-title":"Br. J. Haematol."},{"key":"9653_CR12","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani, K., Rouce, R., Liu, E. & Shpall, E. EngineEring natural killer cells for cancer immunotherapy. Mol. Ther. 25, 1769\u20131781 (2017).","journal-title":"Mol. Ther."},{"key":"9653_CR13","doi-asserted-by":"crossref","unstructured":"Daher, M., Melo Garcia, L., Li, Y. & Rezvani, K. CAR-NK cells: The next wave of cellular therapy for cancer. Clin. Transl. Immunol. 10, (2021).","DOI":"10.1002\/cti2.1274"},{"key":"9653_CR14","doi-asserted-by":"crossref","unstructured":"Lu, H., Zhao, X., Li, Z., Hu, Y. & Wang, H. From CAR-T Cells to CAR-NK Cells: A developing immunotherapy method for hematological malignancies. Front Oncol. 11, 720501 (2021).","DOI":"10.3389\/fonc.2021.720501"},{"key":"9653_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu, J. et al. Natural killer cells: a promising immunotherapy for cancer. J. Transl. Med 20, 240 (2022).","journal-title":"J. Transl. Med"},{"key":"9653_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso, S. et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J. Hematol. Oncol. 15, 163 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"9653_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski, A. et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J. Cell Mol. Med. 20, 1287\u20131294 (2016).","journal-title":"J. Cell Mol. Med."},{"key":"9653_CR18","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2021-148649","volume":"138","author":"E Choi","year":"2021","unstructured":"Choi, E. et al. Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies. Blood 138, 1691\u20131691 (2021).","journal-title":"Blood"},{"key":"9653_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity. Leukemia 32, 520 (2018).","journal-title":"Leukemia"},{"key":"9653_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","volume":"42","author":"M Shanley","year":"2024","unstructured":"Shanley, M. et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell 42, 1450\u20131466.e11 (2024).","journal-title":"Cancer Cell"},{"key":"9653_CR21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1158\/2326-6066.CIR-22-0017","volume":"10","author":"EH Knelson","year":"2022","unstructured":"Knelson, E. H. et al. Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol. Res 10, 947\u2013961 (2022).","journal-title":"Cancer Immunol. Res"},{"key":"9653_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624 (2021).","journal-title":"Blood"},{"key":"9653_CR23","doi-asserted-by":"publisher","first-page":"eadd6997","DOI":"10.1126\/sciadv.add6997","volume":"9","author":"L Li","year":"2023","unstructured":"Li, L. et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci. Adv. 9, eadd6997 (2023).","journal-title":"Sci. Adv."},{"key":"9653_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00355-3","volume":"10","author":"DC Kirouac","year":"2024","unstructured":"Kirouac, D. C., Zmurchok, C. & Morris, D. Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics. NPJ Syst. Biol. Appl 10, 31 (2024).","journal-title":"NPJ Syst. Biol. Appl"},{"key":"9653_CR25","first-page":"114","volume":"6","author":"IWY Mak","year":"2014","unstructured":"Mak, I. W. Y., Evaniew, N. & Ghert, M. Lost in translation: Animal models and clinical trials in cancer treatment. Am. J. Transl. Res 6, 114 (2014).","journal-title":"Am. J. Transl. Res"},{"key":"9653_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/spmg.19885","volume":"2","author":"G Kaur","year":"2012","unstructured":"Kaur, G. & Dufour, J. M. Cell lines: Valuable tools or useless artifacts. Spermatogenesis 2, 1\u20135 (2012).","journal-title":"Spermatogenesis"},{"key":"9653_CR27","doi-asserted-by":"crossref","unstructured":"Yang, S. et al. Organoids: The current status and biomedical applications. MedComm (Beijing) 4, e274 (2023).","DOI":"10.1002\/mco2.274"},{"key":"9653_CR28","doi-asserted-by":"publisher","unstructured":"Metzcar, J., Wang, Y., Heiland, R. & Macklin, P. A review of cell-based computational modeling in cancer biology. JCO Clin. Cancer Inform 1\u201313 https:\/\/doi.org\/10.1200\/cci.18.00069 (2019).","DOI":"10.1200\/cci.18.00069"},{"key":"9653_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.tibtech.2020.07.006","volume":"39","author":"A del Sol","year":"2021","unstructured":"del Sol, A. & Jung, S. The importance of computational modeling in stem cell research. Trends Biotechnol. 39, 126\u2013136 (2021).","journal-title":"Trends Biotechnol."},{"key":"9653_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1462-5822.2009.01281.x","volume":"11","author":"DE Kirschner","year":"2009","unstructured":"Kirschner, D. E. & Linderman, J. J. Mathematical and computational approaches can complement experimental studies of host\u2013pathogen interactions. Cell Microbiol 11, 531\u2013539 (2009).","journal-title":"Cell Microbiol"},{"key":"9653_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-bioeng-071811-150104","volume":"15","author":"J Walpole","year":"2013","unstructured":"Walpole, J., Papin, J. A. & Peirce, S. M. Multiscale computational models of complex biological systems. Annu Rev. Biomed. Eng. 15, 137\u2013154 (2013).","journal-title":"Annu Rev. Biomed. Eng."},{"key":"9653_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.it.2008.08.006","volume":"29","author":"AK Chavali","year":"2008","unstructured":"Chavali, A. K. et al. Characterizing emergent properties of immunological systems with multi-cellular rule-based computational modeling. Trends Immunol. 29, 589\u2013599 (2008).","journal-title":"Trends Immunol."},{"key":"9653_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semcdb.2015.07.001","volume":"47\u201348","author":"GW Brodland","year":"2015","unstructured":"Brodland, G. W. How computational models can help unlock biological systems. Semin Cell Dev. Biol. 47\u201348, 62\u201373 (2015).","journal-title":"Semin Cell Dev. Biol."},{"key":"9653_CR34","doi-asserted-by":"publisher","unstructured":"Gilpin, L. H. et al. Explaining explanations: An overview of interpretability of machine learning. Proceedings - 2018 IEEE 5th International Conference on Data Science and Advanced Analytics, DSAA 2018 80\u201389 https:\/\/doi.org\/10.1109\/DSAA.2018.00018 (2019).","DOI":"10.1109\/DSAA.2018.00018"},{"key":"9653_CR35","doi-asserted-by":"crossref","unstructured":"Feinberg, A. P. & Levchenko, A. Epigenetics as a mediator of plasticity in cancer. Science (1979) 379, (2023).","DOI":"10.1126\/science.aaw3835"},{"key":"9653_CR36","doi-asserted-by":"crossref","unstructured":"Gong, C. et al. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. J R Soc. Interface 14, 20170320 (2017).","DOI":"10.1098\/rsif.2017.0320"},{"key":"9653_CR37","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1073\/pnas.082080899","volume":"99","author":"E Bonabeau","year":"2002","unstructured":"Bonabeau, E. Agent-based modeling: Methods and techniques for simulating human systems. Proc. Natl. Acad. Sci. USA 99, 7280\u20137287 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9653_CR38","doi-asserted-by":"publisher","unstructured":"Laubenbacher, R., Hinkelmann, F. & Oremland, M. AgeNt-based Models And Optimal Control In Biology: A Discrete Approach. Mathematical Concepts and Methods in Modern Biology: Using Modern Discrete Models 143\u2013178 (2013) https:\/\/doi.org\/10.1016\/B978-0-12-415780-4.00005-3.","DOI":"10.1016\/B978-0-12-415780-4.00005-3"},{"key":"9653_CR39","doi-asserted-by":"publisher","unstructured":"Niida, A., Iwasaki, W. M., Niida, A. & Iwasaki, W. M. Agent-based modeling and analysis of cancer evolution. Simul. Model. https:\/\/doi.org\/10.5772\/INTECHOPEN.100140 (2021).","DOI":"10.5772\/INTECHOPEN.100140"},{"key":"9653_CR40","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1158\/0008-5472.CAN-17-2006","volume":"77","author":"JN Kather","year":"2017","unstructured":"Kather, J. N. et al. In silico modeling of immunotherapy and stroma-targeting therapies in human colorectal cancer. Cancer Res. 77, 6442\u20136452 (2017).","journal-title":"Cancer Res"},{"key":"9653_CR41","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.csbj.2023.02.014","volume":"21","author":"J Retzlaff","year":"2023","unstructured":"Retzlaff, J., Lai, X., Berking, C. & Vera, J. Integration of transcriptomics data into agent-based models of solid tumor metastasis. Comput Struct. Biotechnol. J. 21, 1930 (2023).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"9653_CR42","doi-asserted-by":"publisher","first-page":"e0184229","DOI":"10.1371\/journal.pone.0184229","volume":"12","author":"WM Iwasaki","year":"2017","unstructured":"Iwasaki, W. M. & Innan, H. Simulation framework for generating intratumor heterogeneity patterns in a cancer cell population. PLoS One 12, e0184229 (2017).","journal-title":"PLoS One"},{"key":"9653_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/S41587-023-01687-X","author":"DC Kirouac","year":"2023","unstructured":"Kirouac, D. C. et al. Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/S41587-023-01687-X (2023).","journal-title":"Nat. Biotechnol."},{"key":"9653_CR44","doi-asserted-by":"crossref","unstructured":"Rezvani, K. & Rouce, R. H. The application of natural killer cell immunotherapy for the treatment of cancer. Front. Immunol. 6, 578 (2015).","DOI":"10.3389\/fimmu.2015.00578"},{"key":"9653_CR45","doi-asserted-by":"crossref","unstructured":"Pouxvielh, K. et al. Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints. Sci. Adv. 10, eadn0164 (2024).","DOI":"10.1126\/sciadv.adn0164"},{"key":"9653_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri3044","volume":"11","author":"JC Sun","year":"2011","unstructured":"Sun, J. C. & Lanier, L. L. NK cell development, homeostasis and function: Parallels with CD8+T cells. Nat. Rev. Immunol. 11, 645\u2013657 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"9653_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1084\/jem.20100479","volume":"208","author":"JC Sun","year":"2011","unstructured":"Sun, J. C., Beilke, J. N., Bezman, N. A. & Lanier, L. L. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J. Exp. Med 208, 357 (2011).","journal-title":"J. Exp. Med"},{"key":"9653_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","volume":"457","author":"JC Sun","year":"2009","unstructured":"Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer cells. Nature 457, 557\u2013561 (2009).","journal-title":"Nature"},{"key":"9653_CR49","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva, O. et al. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity 56, 2816\u20132835.e13 (2023).","journal-title":"Immunity"},{"key":"9653_CR50","doi-asserted-by":"publisher","first-page":"E11731","DOI":"10.1073\/pnas.1814052115","volume":"115","author":"X Du","year":"2018","unstructured":"Du, X. et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc. Natl. Acad. Sci. USA 115, E11731\u2013E11740 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9653_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12113285","volume":"12","author":"L Quatrini","year":"2020","unstructured":"Quatrini, L. et al. The immune checkpoint PD\u22121 in natural killer cells: Expression, function and targeting in tumour immunotherapy. Cancers (Basel) 12, 1\u201321 (2020).","journal-title":"Cancers (Basel)"},{"key":"9653_CR52","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u20134251.e20 (2023).","journal-title":"Cell"},{"key":"9653_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran, G. H., Lin, Y. Q., Tian, L., Zhang, T., Yan, D. M., Yu, J. H. & Deng, Y. C. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct. Target Ther. 7, 205 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"9653_CR54","first-page":"1","volume":"8","author":"L Sanz-Ortega","year":"2024","unstructured":"Sanz-Ortega, L. et al. Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity. NPJ Precis Oncol. 8, 1\u201312 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"9653_CR55","doi-asserted-by":"publisher","unstructured":"Yokoyama, W. M., Kim, S. & French, A. R. The dynamic life of natural killer cells. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104711 22, 405\u2013429 (2004).","DOI":"10.1146\/annurev.immunol.22.012703.104711"},{"key":"9653_CR56","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4049\/jimmunol.172.2.864","volume":"172","author":"AM Jamieson","year":"2004","unstructured":"Jamieson, A. M., Isnard, P., Dorfman, J. R., Coles, M. C. & Raulet, D. H. Turnover and proliferation of NK cells in steady state and lymphopenic conditions.  J. Immunol. 172, 864\u2013870 (2004).","journal-title":"J. Immunol."},{"key":"9653_CR57","doi-asserted-by":"publisher","first-page":"e005678","DOI":"10.1136\/jitc-2022-005678","volume":"10","author":"A Rotte","year":"2022","unstructured":"Rotte, A. et al. Dose\u2013response correlation for CAR-T cells: A systematic review of clinical studies. J. Immunother. Cancer 10, e005678 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"9653_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13046-022-02540-w","volume":"42","author":"M Frigault","year":"2023","unstructured":"Frigault, M. et al. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. J. Exp. Clin. Cancer Res. 42, 11 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"9653_CR59","doi-asserted-by":"crossref","unstructured":"He, J. et al. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors. Front. Immunol. 14, 1298683 (2023).","DOI":"10.3389\/fimmu.2023.1298683"},{"key":"9653_CR60","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jcyt.2021.03.006","volume":"23","author":"T Mamo","year":"2021","unstructured":"Mamo, T. et al. Infusion reactions in natural killer cell immunotherapy: a retrospective review. Cytotherapy 23, 627\u2013634 (2021).","journal-title":"Cytotherapy"},{"key":"9653_CR61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cels.2024.03.004","volume":"15","author":"JW Hickey","year":"2024","unstructured":"Hickey, J. W. et al. Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy. Cell Syst. 15, 322\u2013338.e5 (2024).","journal-title":"Cell Syst."},{"key":"9653_CR62","unstructured":"Dondossola, E. & La Posta, L. Natural Killer Cell Biology Study. Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Preprint at (2025)."},{"key":"9653_CR63","doi-asserted-by":"crossref","unstructured":"Cogno, N., Axenie, C., Bauer, R. & Vavourakis, V. Agent-based modeling in cancer biomedicine: Applications and tools for calibration and validation. Cancer Biol. Ther. 25, 2344600 (2024).","DOI":"10.1080\/15384047.2024.2344600"},{"key":"9653_CR64","doi-asserted-by":"crossref","unstructured":"Kazil Jackie and Masad, D. and C. A. Utilizing Python for Agent-Based Modeling: The Mesa Framework. in Social, Cultural, and Behavioral Modeling (ed. Thomson Robert and Bisgin, H. and D. C. and H. A. and H. M.) 308\u2013317 (Springer International Publishing, Cham, 2020).","DOI":"10.1007\/978-3-030-61255-9_30"},{"key":"9653_CR65","doi-asserted-by":"publisher","unstructured":"Leonard-Duke, J. et al. Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease. https:\/\/doi.org\/10.1101\/2024.03.15.585249 (2024).","DOI":"10.1101\/2024.03.15.585249"},{"key":"9653_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52480-3","volume":"9","author":"T Kwon","year":"2019","unstructured":"Kwon, T., Kwon, O.-S., Cha, H.-J. & Sung, B. J. Stochastic and Heterogeneous Cancer Cell Migration: Experiment and Theory. Sci. Rep. 9, 16297 (2019).","journal-title":"Sci. Rep."},{"key":"9653_CR67","doi-asserted-by":"crossref","unstructured":"Herrera, L. et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci. Rep. 2019 9:1 9, 1\u201310 (2019).","DOI":"10.1038\/s41598-019-55239-y"},{"key":"9653_CR68","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/aor.14503","volume":"47","author":"JJ Han","year":"2023","unstructured":"Han, J. J. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif. Organs 47, 449\u2013450 (2023).","journal-title":"Artif. Organs"},{"key":"9653_CR69","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood-2012-06-439851","volume":"121","author":"B Vanherberghen","year":"2013","unstructured":"Vanherberghen, B. et al. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood 121, 1326\u20131334 (2013).","journal-title":"Blood"},{"key":"9653_CR70","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3389\/fimmu.2018.02324","volume":"9","author":"R Castriconi","year":"2018","unstructured":"Castriconi, R. et al. Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues. Front Immunol. 9, 2324 (2018).","journal-title":"Front Immunol."},{"key":"9653_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","volume":"128","author":"NJ Topham","year":"2009","unstructured":"Topham, N. J. & Hewitt, E. W. Natural killer cell cytotoxicity: How do they pull the trigger?. Immunology 128, 7 (2009).","journal-title":"Immunology"},{"key":"9653_CR72","doi-asserted-by":"publisher","first-page":"290728","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul, S. & Lal, G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 8, 290728 (2017).","journal-title":"Front Immunol."},{"key":"9653_CR73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: Fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"9653_CR74","doi-asserted-by":"crossref","unstructured":"Hermans, L. & O\u2019Sullivan, T. E. No time to die: Epigenetic regulation of natural killer cell survival. Immunol Rev. 323, 61\u201379 (2024).","DOI":"10.1111\/imr.13314"},{"key":"9653_CR75","doi-asserted-by":"publisher","unstructured":"Padmanabhan, R. & Meskin, N. Mathematical modeling on immunotherapy and its application for deriving cancer therapy. in Handbook of Cancer and Immunology 1\u201333 (Springer International Publishing, Cham, 2022). https:\/\/doi.org\/10.1007\/978-3-030-80962-1_314-1.","DOI":"10.1007\/978-3-030-80962-1_314-1"},{"key":"9653_CR76","doi-asserted-by":"publisher","first-page":"e004104","DOI":"10.1136\/jitc-2021-004104","volume":"10","author":"JA Hangasky","year":"2022","unstructured":"Hangasky, J. A. et al. A very long-acting IL-15: Implications for the immunotherapy of cancer. J. Immunother. Cancer 10, e004104 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"9653_CR77","doi-asserted-by":"crossref","unstructured":"Bhat, R. & Watzl, C. Serial killing of tumor cells by human natural killer cells - Enhancement by therapeutic antibodies. PLoS One 2, e326 (2007).","DOI":"10.1371\/journal.pone.0000326"},{"key":"9653_CR78","doi-asserted-by":"crossref","unstructured":"Stary, V. & Stary, G. NK cell-mediated recall responses: Memory-like, adaptive, or antigen-specific? Front. Cell. Infect. Microbiol. 10, 208 (2020).","DOI":"10.3389\/fcimb.2020.00208"},{"key":"9653_CR79","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood.2020006619","volume":"136","author":"M Gang","year":"2020","unstructured":"Gang, M. et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood 136, 2308 (2020).","journal-title":"Blood"},{"key":"9653_CR80","doi-asserted-by":"crossref","unstructured":"Paust, S., Blish, C. A. & Reeves, R. K. Redefining memory: Building the case for adaptive NK Cells. J. Virol, 91, e00169-17 (2017).","DOI":"10.1128\/JVI.00169-17"},{"key":"9653_CR81","doi-asserted-by":"crossref","unstructured":"Guo, C. et al. Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19. Genome Med. 14, 46 (2022).","DOI":"10.1186\/s13073-022-01049-3"},{"key":"9653_CR82","doi-asserted-by":"crossref","unstructured":"Sherr, C. J. Cancer cell cycles. Science (1979) 274,(1996).","DOI":"10.1126\/science.274.5293.1672"},{"key":"9653_CR83","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/cncy.20075","volume":"118","author":"AE Ali","year":"2010","unstructured":"Ali, A. E. et al. Classifying B-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates. Cancer Cytopathol. 118, 166\u2013172 (2010).","journal-title":"Cancer Cytopathol."},{"key":"9653_CR84","doi-asserted-by":"crossref","unstructured":"Feucht, D. et al. Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival. Neurooncol. Adv. 6, vdae053 (2024).","DOI":"10.1093\/noajnl\/vdae053"},{"key":"9653_CR85","doi-asserted-by":"publisher","first-page":"14295","DOI":"10.1073\/pnas.97.26.14295","volume":"97","author":"P Duesberg","year":"2000","unstructured":"Duesberg, P., Stindl, R. & Hehlmann, R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc. Natl. Acad. Sci. USA 97, 14295\u201314300 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9653_CR86","doi-asserted-by":"crossref","unstructured":"Liang, Q., Huang, Y., He, S. & Chen, K. Pathway centric analysis for single-cell RNA-seq and spatial transcriptomics data with GSDensity. Nat. Commun. 2023 14:1 14, 1\u201317 (2023).","DOI":"10.1038\/s41467-023-44206-x"},{"key":"9653_CR87","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long, E. O., Sik Kim, H., Liu, D., Peterson, M. E. & Rajagopalan, S. Controlling NK cell responses: Integration of signals for activation and inhibition. Annu Rev. Immunol. 31, 227\u2013258 (2013).","journal-title":"Annu Rev. Immunol."},{"key":"9653_CR88","doi-asserted-by":"crossref","unstructured":"Jia, H., Yang, H., Xiong, H. & Luo, K. Q. NK cell exhaustion in the tumor microenvironment. Front. Immunol. 14, 1303605 (2023).","DOI":"10.3389\/fimmu.2023.1303605"},{"key":"9653_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25715-z","volume":"12","author":"E Littwitz-Salomon","year":"2021","unstructured":"Littwitz-Salomon, E. et al. Metabolic requirements of NK cells during the acute response against retroviral infection. Nat. Commun. 12, 5376 (2021).","journal-title":"Nat. Commun."},{"key":"9653_CR90","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/eji.201545480","volume":"45","author":"F Wang","year":"2015","unstructured":"Wang, F. et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur. J. Immunol. 45, 2886\u20132897 (2015).","journal-title":"Eur. J. Immunol."},{"key":"9653_CR91","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-014-1629-5","volume":"64","author":"E Wennerberg","year":"2015","unstructured":"Wennerberg, E., Kremer, V., Childs, R. & Lundqvist, A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol., Immunother. 64, 225\u2013235 (2015).","journal-title":"Cancer Immunol., Immunother."},{"key":"9653_CR92","doi-asserted-by":"crossref","unstructured":"Bates, D., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1\u201348 (2015).","DOI":"10.18637\/jss.v067.i01"},{"key":"9653_CR93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3892\/ijo.2023.5516","volume":"62","author":"D-H Liu","year":"2023","unstructured":"Liu, D.-H., Mou, F.-F., An, M. & Xia, P. Human leukocyte antigen and tumor immunotherapy (Review). Int J. Oncol. 62, 68 (2023).","journal-title":"Int J. Oncol."},{"key":"9653_CR94","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/ijms20061483","volume":"20","author":"P Savoia","year":"2019","unstructured":"Savoia, P., Fava, P. & Casoni, F. & Cremona, O. Targeting the ERK signaling pathway in melanoma. Int J. Mol. Sci. 20, 1483 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"9653_CR95","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","volume":"124","author":"NM Novikov","year":"2021","unstructured":"Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M. & Denisov, E. V. Mutational drivers of cancer cell migration and invasion. Br. J. Cancer 124, 102\u2013114 (2021).","journal-title":"Br. J. Cancer"},{"key":"9653_CR96","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.trecan.2020.02.021","volume":"6","author":"AC Cannon","year":"2020","unstructured":"Cannon, A. C., Uribe-Alvarez, C. & Chernoff, J. RAC1 as a therapeutic target in malignant melanoma. Trends Cancer 6, 478\u2013488 (2020).","journal-title":"Trends Cancer"},{"key":"9653_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21535-3","volume":"12","author":"F Zheng","year":"2021","unstructured":"Zheng, F. et al. The HIF-1\u03b1 antisense long non-coding RNA drives a positive feedback loop of HIF-1\u03b1 mediated transactivation and glycolysis. Nat. Commun. 12, 1341 (2021).","journal-title":"Nat. Commun."},{"key":"9653_CR98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang, Y. & Cao, Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 86, 251\u2013261 (2022).","journal-title":"Semin Cancer Biol."},{"key":"9653_CR99","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: Machine learning in python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"9653_CR100","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv 060012 https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"9653_CR101","unstructured":"Scornet, E. Trees, forests, and impurity-based variable importance in regression. Annales de l\u2019Institut Henri Poincar\u00e9, Probabilit\u00e9s et Statistiques https:\/\/api.semanticscholar.org\/CorpusID:210164587 (2020)."},{"key":"9653_CR102","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/bioinformatics\/btq134","volume":"26","author":"A Altmann","year":"2010","unstructured":"Altmann, A., Tolo\u015fi, L., Sander, O. & Lengauer, T. Permutation importance: a corrected feature importance measure. Bioinformatics 26, 1340\u20131347 (2010).","journal-title":"Bioinformatics"},{"key":"9653_CR103","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s13239-018-00372-4","volume":"9","author":"A Nikishova","year":"2018","unstructured":"Nikishova, A., Veen, L., Zun, P. & Hoekstra, A. G. Uncertainty Quantification of a Multiscale Model for In-Stent Restenosis. Cardiovasc Eng. Technol. 9, 761\u2013774 (2018).","journal-title":"Cardiovasc Eng. Technol."},{"key":"9653_CR104","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.21105\/joss.07754","volume":"10","author":"J Boelts","year":"2025","unstructured":"Boelts, J. et al. sbi reloaded: a toolkit for simulation-based inference workflows. J. Open Source Softw. 10, 7754 (2025).","journal-title":"J. Open Source Softw."},{"key":"9653_CR105","unstructured":"Papamakarios, G. & Murray, I. Fast \u03b5-free inference of simulation models with Bayesian conditional density estimation. In Proceedings of the 30th International Conference on Neural Information Processing Systems (NIPS'16). 1036\u20131044 (Curran Associates Inc., Red Hook, NY, USA, 2016)."},{"key":"9653_CR106","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.matcom.2016.05.008","volume":"133","author":"A Jalalimanesh","year":"2017","unstructured":"Jalalimanesh, A., Shahabi Haghighi, H., Ahmadi, A. & Soltani, M. Simulation-based optimization of radiotherapy: Agent-based modeling and reinforcement learning. Math. Comput Simul. 133, 235\u2013248 (2017).","journal-title":"Math. Comput Simul."},{"key":"9653_CR107","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours\u2014implications for treatment response. Br. J. Radio. 87, 20130676 (2014).","journal-title":"Br. J. Radio."},{"key":"9653_CR108","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2022)."},{"key":"9653_CR109","unstructured":"Foundation, P. S. Python 3.9: A Programming Language. https:\/\/www.python.org\/ (2020)."},{"key":"9653_CR110","doi-asserted-by":"crossref","unstructured":"Olofsson, P. E. et al. Distinct migration and contact dynamics of resting and IL-2-activated human natural killer cells. Front. Immunol. 5, 80 (2014).","DOI":"10.3389\/fimmu.2014.00080"},{"key":"9653_CR111","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1182\/blood-2016-09-738211","volume":"129","author":"S Bhatt","year":"2017","unstructured":"Bhatt, S. et al. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell\u2013dependent cytotoxicity. Blood 129, 2246\u20132256 (2017).","journal-title":"Blood"},{"key":"9653_CR112","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang, K., Wei, G. & Liu, D. CD19: A biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1, 36 (2012).","journal-title":"Exp. Hematol. Oncol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09653-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:01:56Z","timestamp":1774011716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09653-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9653"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09653-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.Da., R.B., M.S., and K.R., and the University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical. R.B., K.R., and the University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Affimed GmbH. K.R. participates on the Scientific Advisory Board for Avenge Bio, Virogin Biotech, Navan Technologies, Caribou Biosciences, Bit Bio Limited, Replay Holdings, oNKo Innate, and The Alliance for Cancer Gene Therapy ACGT. K.R. is the Scientific founder of Syena. M. Da. participates on the Scientific Advisory Board for Cellsbin.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}